

Eyecuracy mission is to revolutionize in-office and at-home care for over hundreds of millions suffering from neurological diseases

Our 1st Market - Binocular Vision Disorders

Our main advantage lies in our unique highly accessible AI-powered eye tracking technology, delivering 0.4° accuracy without user calibration versus the industry's 2°-3°.

Replacing current manual, inaccurate, time consuming procedures with fast, objective and accurate Eyecuracy solution will increase revenues for providers and make it more accessible to patients.

MARKET OPPORTUNITY

Binocular Vision Disorders (BVD) is the fastest path to market. Over 33 million Americans suffer from BVDs, yet only a small fraction are diagnosed or treated! Current diagnostic procedures are manual, slow, rely on patient's reports and require high clinical skills - resulting in missed diagnostics, poor monitoring, and ineffective treatment.

Eyecuracy addresses a gap with objective, accurate, scalable diagnostics and monitoring of **BVDs - over \$360M annual US market.**

Expansion into broader neurological conditions: Parkinson's, Multiple Sclerosis, concussions and more further down the road.

"You cannot treat what you cannot measure!" - BVD and eye movement biomarkers unlock a **multi-billion-dollar opportunity!**


EYECURACY SOLUTION

Eyecuracy's solution is a hybrid healthcare platform featuring a user-friendly, simple, and affordable eye tracking glasses combined with smart cloud service running proprietary AI algorithms.

It relies on a first-of-its-kind, high accuracy, user friendly, fully patent protected, AI-powered Eye Tracking technology that detects relevant digital biomarkers without a need for tedious user calibrations.

BUSINESS MODEL

Eyecuracy targets optometry, ophthalmology, and neurology clinics that will buy or lease Eyecuracy products for more effective diagnostics, and then give them to patients to be used in their homes for further monitoring, treatment, and telehealth support



CURRENT STATE

- ✓ 4 working prototypes, rich software framework, and powerful AI platform.
- ✓ 4 patents families registered in major markets - USA, Europe, China, Japan, Taiwan.
8 patents granted in 2025-2026!
- ✓ **5 highly successful Pilot Studies** at UC Berkeley School of Optometry and at University of Regensburg Eye Clinic
- ✓ **NRE & Royalties agreement** with major brain-surgery equipment vendor
expected revenues from royalties - **\$150K in 2027, \$300K in 2028**

TEAM

Eyecuracy has a strong team of seasoned managers, engineers, and scientists, an extensive advisory board consisting of industry thought leaders.



Albert Kashchenevsky
CEO



Anatoly Vorobey
Head of Software R&D



Rani Cohen
Active Chairman



Mark Shovman, PhD
Vision Scientist